title: Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
authors: Kenjiro
authors: K
authors: Mitsuhashi
authors: Midori
authors: M
authors: Ishiyama
authors: Yoichi
authors: Y
authors: Imai
authors: Masayuki
authors: M
authors: Shiseki
authors: Naoki
authors: N
authors: Mori
authors: Masanao
authors: M
authors: Teramura
authors: Akiyoshi
authors: A
authors: Seshimo
authors: Toshiko
authors: T
authors: Motoji
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D001792:Blood Platelets / Q000276:immunology; D003131:Combined Modality Therapy; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D010976:Platelet Count; D011300:Preoperative Care; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011961:Receptors, Fc / Q000008:administration & dosage / Q000627:therapeutic use*; D053628:Receptors, Thrombopoietin / Q000819:agonists*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D000069283:Rituximab; D013156:Splenectomy; D013926:Thrombopoietin / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D011961:Receptors, Fc; D053628:Receptors, Thrombopoietin; D011993:Recombinant Fusion Proteins; C082218:MPL protein, human; D000069283:Rituximab; D013926:Thrombopoietin; C488777:romiplostim